150 related articles for article (PubMed ID: 34664209)
1. Evaluation of the Robustness of Therapeutic Drug Monitoring Coupled with Bayesian Forecasting of Busulfan with Regard to Inaccurate Documentation.
Dadkhah A; Alihodzic D; Broeker A; Kröger N; Langebrake C; Wicha SG
Pharm Res; 2021 Oct; 38(10):1721-1729. PubMed ID: 34664209
[TBL] [Abstract][Full Text] [Related]
2. Impact of Inaccurate Documentation of Sampling and Infusion Time in Model-Informed Precision Dosing.
Alihodzic D; Broeker A; Baehr M; Kluge S; Langebrake C; Wicha SG
Front Pharmacol; 2020; 11():172. PubMed ID: 32194411
[TBL] [Abstract][Full Text] [Related]
3. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS
J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185
[TBL] [Abstract][Full Text] [Related]
4. Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients.
Ben Hassine K; Daali Y; Gloor Y; Nava T; Théorêt Y; Krajinovic M; Bittencourt H; Satyanarayana Uppugunduri CR; Ansari M
Ther Drug Monit; 2024 Jun; ():. PubMed ID: 38885146
[TBL] [Abstract][Full Text] [Related]
5. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.
Vaughan WP; Carey D; Perry S; Westfall AO; Salzman DE
Biol Blood Marrow Transplant; 2002; 8(11):619-24. PubMed ID: 12463481
[TBL] [Abstract][Full Text] [Related]
6. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation.
Lawson R; Paterson L; Fraser CJ; Hennig S
Cancer Chemother Pharmacol; 2021 Sep; 88(3):379-391. PubMed ID: 34021809
[TBL] [Abstract][Full Text] [Related]
8. Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations.
Yuan J; Sun N; Feng X; He H; Mei D; Zhu G; Zhao L
Pharmgenomics Pers Med; 2021; 14():253-268. PubMed ID: 33623415
[TBL] [Abstract][Full Text] [Related]
9. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
Neroutsos E; Athanasiadou I; Paisiou A; Zisaki K; Goussetis E; Archontaki H; Tsirigotis P; Kitra M; Grafakos S; Spyridonidis A; Dokoumetzidis A; Valsami G
J Pharm Pharmacol; 2021 Sep; 73(10):1340-1350. PubMed ID: 34244783
[TBL] [Abstract][Full Text] [Related]
10. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.
Broeker A; Nardecchia M; Klinker KP; Derendorf H; Day RO; Marriott DJ; Carland JE; Stocker SL; Wicha SG
Clin Microbiol Infect; 2019 Oct; 25(10):1286.e1-1286.e7. PubMed ID: 30872102
[TBL] [Abstract][Full Text] [Related]
11. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing.
Hughes JH; Long-Boyle J; Keizer RJ
J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):279-288. PubMed ID: 38520573
[TBL] [Abstract][Full Text] [Related]
12. Limited Sampling Strategies for Estimating Busulfan Area Under the Concentration-Time Curve: Based on Peak and Trough Concentrations in Saliva.
Xu B; Zhou J; Zheng Y; Xu R; Liu Q; Li D; Liu M; Wu X
J Clin Pharmacol; 2024 Jan; 64(1):58-66. PubMed ID: 37697452
[TBL] [Abstract][Full Text] [Related]
13. Limited Sampling Strategies Supporting Individualized Dose Adjustment of Intravenous Busulfan in Children and Young Adults.
Teitelbaum Z; Nassar L; Scherb I; Fink D; Ring G; Lurie Y; Krivoy N; Bentur Y; Efrati E; Kurnik D
Ther Drug Monit; 2020 Jun; 42(3):427-434. PubMed ID: 31479045
[TBL] [Abstract][Full Text] [Related]
14. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.
Tesfaye H; Branova R; Klapkova E; Prusa R; Janeckova D; Riha P; Sedlacek P; Keslova P; Malis J
Ann Transplant; 2014 May; 19():214-24. PubMed ID: 24811685
[TBL] [Abstract][Full Text] [Related]
15. Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved?
Buffery PJ; Allen KM; Chin PK; Moore GA; Barclay ML; Begg EJ
Ther Drug Monit; 2014 Feb; 36(1):86-92. PubMed ID: 24299921
[TBL] [Abstract][Full Text] [Related]
16. Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study.
Xu B; Yang T; Zhou J; Zheng Y; Wang J; Liu Q; Li D; Zhang Y; Liu M; Wu X
CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1238-1249. PubMed ID: 37491812
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
[TBL] [Abstract][Full Text] [Related]
18. Two-point blood sampling is sufficient and necessary to estimate the area under the concentration-time curve for intravenous busulfan in infants and young children.
Utano T; Kato M; Sakamoto K; Osumi T; Matsumoto K; Tomizawa D; Matsumoto K; Yamatani A
Pediatr Blood Cancer; 2021 Aug; 68(8):e29069. PubMed ID: 33881202
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
20. Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation.
Bullock JM; Smith PF; Booker BM; Loughner J; Capozzi D; McCarthy PL; Shaw LM
Ther Drug Monit; 2006 Feb; 28(1):62-6. PubMed ID: 16418695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
